(MONT)
NASDAQ:MONTMonster Arts, Inc. is a technology company. It operates through its subsidiaries, organizes advertising sales efforts by constructing media and advertising delivery systems for smartphone and tablet application developers including the delivery of mobile banners, mobile video, mobile text messaging, and mobile email advertising. The company also engages in the development of next generation tracking software's that run on devices controlled by the very same smart device platform technologies. It develops software developer for mobile devices, smart TVs, and set top boxes running iOS, Android, Windows and other platforms. Monster Arts was founded on February 23, 2007 and is headquartered in Las Vegas, NV.
(MY)
NYSE:MYChina Ming Yang Wind Power Group Limited is a wind turbine manufacturer in China, focusing on designing, manufacturing, selling and servicing megawatt-class wind turbines. The Company's products consist of basic models of wind turbines with a rated power capacity of 1.5 megawatts, wind turbines with a rated power capacity of 2.0 megawatts, 2.5/3.0 megawatts super compact drive (SCD) and 6.0/6.5 megawatts SCD wind turbines. The Company produces megawatt-class, grid-connected, horizontal-axis wind turbines, equipped with a double-fed constant frequency induction generator, which is a design of the generator that enables the generator to produce electric current of a constant frequency as the shaft rotates at varying speeds causing the generator rotor to rotate at varying speed. The Company's products include MY1.5/2.0 Ambient Temperature Model, MY1.5/2.0 Anti-low Temperature Resistant Model, Other MY1.5/2.0 Customized Models, SCD Wind Turbines and MySE Wind Turbines.
Mylan
NASDAQ:MYLMylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.